Activity of MDI-301, a novel synthetic retinoid, in xenografts

Virginia C.L. Appleyard; Mary A. O'Neill; Karen E. Murray; Susan E. Bray; George Thomson; Neil M. Kernohan; James Varani; Jian Zhang; Alastair M. Thompson

doi:10.1097/00001813-200411000-00009

Activity of MDI-301, a novel synthetic retinoid, in xenografts

Virginia C.L. Appleyard, Mary A. O'Neill, Karen E. Murray, Susan E. Bray, George Thomson, Neil M. Kernohan, James Varani, Jian Zhang, Alastair M. Thompson

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen-dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) α. Both retinoids also showed similar efficacy against established PC-3 prostate carcinoma xenografts. MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. Tumor xenografts derived from MDA-MB-231, an estrogen-independent breast cancer cell line that expresses low levels of RARα, were unresponsive. This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARα, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy.

Original language	English (US)
Pages (from-to)	991-996
Number of pages	6
Journal	Anti-cancer drugs
Volume	15
Issue number	10
DOIs	https://doi.org/10.1097/00001813-200411000-00009
State	Published - Nov 2004

Keywords

Breast cancer
Prostate cancer
Retinoids
Synthetic retinoids
Xenografts

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Cancer Research

Access to Document

10.1097/00001813-200411000-00009

Cite this

@article{0ae57449d8c74ec889e1a98f50445b5c,

title = "Activity of MDI-301, a novel synthetic retinoid, in xenografts",

abstract = "The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen-dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) α. Both retinoids also showed similar efficacy against established PC-3 prostate carcinoma xenografts. MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. Tumor xenografts derived from MDA-MB-231, an estrogen-independent breast cancer cell line that expresses low levels of RARα, were unresponsive. This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARα, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy.",

keywords = "Breast cancer, Prostate cancer, Retinoids, Synthetic retinoids, Xenografts",

author = "Appleyard, {Virginia C.L.} and O'Neill, {Mary A.} and Murray, {Karen E.} and Bray, {Susan E.} and George Thomson and Kernohan, {Neil M.} and James Varani and Jian Zhang and Thompson, {Alastair M.}",

year = "2004",

month = nov,

doi = "10.1097/00001813-200411000-00009",

language = "English (US)",

volume = "15",

pages = "991--996",

journal = "Anti-cancer drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Activity of MDI-301, a novel synthetic retinoid, in xenografts

AU - Appleyard, Virginia C.L.

AU - O'Neill, Mary A.

AU - Murray, Karen E.

AU - Bray, Susan E.

AU - Thomson, George

AU - Kernohan, Neil M.

AU - Varani, James

AU - Zhang, Jian

AU - Thompson, Alastair M.

PY - 2004/11

Y1 - 2004/11

N2 - The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen-dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) α. Both retinoids also showed similar efficacy against established PC-3 prostate carcinoma xenografts. MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. Tumor xenografts derived from MDA-MB-231, an estrogen-independent breast cancer cell line that expresses low levels of RARα, were unresponsive. This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARα, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy.

AB - The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen-dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) α. Both retinoids also showed similar efficacy against established PC-3 prostate carcinoma xenografts. MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. Tumor xenografts derived from MDA-MB-231, an estrogen-independent breast cancer cell line that expresses low levels of RARα, were unresponsive. This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARα, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy.

KW - Breast cancer

KW - Prostate cancer

KW - Retinoids

KW - Synthetic retinoids

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=9344219933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344219933&partnerID=8YFLogxK

U2 - 10.1097/00001813-200411000-00009

DO - 10.1097/00001813-200411000-00009

M3 - Article

C2 - 15514569

AN - SCOPUS:9344219933

SN - 0959-4973

VL - 15

SP - 991

EP - 996

JO - Anti-cancer drugs

JF - Anti-cancer drugs

IS - 10

ER -

Activity of MDI-301, a novel synthetic retinoid, in xenografts

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this